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Introduction: APD811 is an oral, non-prostanoid IP receptor agonist with a long plasma 
half-life (∼ 24 hr) in development for pulmonary arterial hypertension (PAH). Little is known 
about the pulmonary pharmacology of this agent. The aim was to compare the functional 
effects of APD811 in distal human pulmonary smooth muscle cells (PASMCs) and arteries 
(PAs) alongside other prostacyclin mimetics already licensed for PAH. 
Methods: PASMCs from PAH patients were grown in 9% serum and treated with IP 
receptor agonists ± 1 μM RO-1138452 (IP receptor antagonist) for 1hr (cyclic AMP) or 96hr 
(cell proliferation). Cyclic AMP was assessed using an ELISA and cell proliferation using an 
MTS assay. Distal PAs from control patients (mean age 66yr) were mounted in a myograph 
and pre-tensioned to an equivalent of ∼22 mmHg (3K Pascal) before being constricted with 
U46619 (thromboxane mimetic; 100nM). The concentration (EC50) producing the half 
maximal response (Emax) was determined. 
Results: Iloprost, APD811, MRE-269 (selexipag metabolite) and treprostinil increased 
cyclic AMP (EC50 17, 252, 340, 550 nM, respectively). Emax was lower (P<0.001; n=5) for all 
three agents (64, 45, 25%, respectively) compared with treprostinil. In proliferation assays, 
APD811 was 10 fold more potent (14 nM) than MRE-269 (145 nM) and Emax were lower for 
both compared to treprostinil (57% versus 89%). RO-1138452 (1 μM) abolished agonist-
induced cAMP generation and the antiproliferative effects of APD811 and MRE-269. In 
contrast, the antiproliferative effects of treprostinil and iloprost were weakly inhibited by RO-
1138452. In PAs, APD811 produced a significantly (P<0.001, n=5–8) greater relaxation 
(Emax 98%) compared to iloprost (Emax 84%), treprostinil (Emax 71%) or MRE-296 (Emax 59%) 
and was more potent than MRE-269 (EC50 449nM versus 1579 nM) but similar to iloprost 
(EC50 650 nM) or treprostinil (EC50=320 nM).  
Conclusions: APD811 and MRE-269 behave as selective, but partial IP receptor agonists, 
whereas iloprost and treprostinil can inhibit cell proliferation through IP-receptor 
independent pathways. In all assays APD811 produced superior effects to MRE-269 and 
had a favourable vasodilator profile compared with iloprost and treprostinil. 
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